<!DOCTYPE html>
<meta http-equiv="Content-Type" content="text/html; charset=UTF-8">
<title>Taltz (Ixekizumab)</title>

<head>
    <link rel="stylesheet" href="style.css">
</head>

<body id="body">

    <nav id="navbar">
        <header>AUSTRALIAN PI - IXEKIZUMAB</header>
        <ol id="navbar-ol">
            <li><a class="nav-link" href="#NAME_OF_THE_MEDICINE">NAME OF THE MEDICINE</a></li>
            <li>
                <a class="nav-link" href="#QUALITATIVE_AND_QUANTITATIVE_COMPOSITION">QUALITATIVE AND QUANTITATIVE COMPOSITION</a>
            </li>


            <li>
                <a class="nav-link" href="PHARMACEUTICAL_FORM">PHARMACEUTICAL FORM</a>
            </li>


            <li><a class="nav-link" href="#CLINICAL_PARTICULARS">CLINICAL PARTICULARS</a>
                <ul id="navbar-ul">
                    <li><a class="nav-link" href="#Therapeutic_indications">4.1 Therapeutic indications </a> </li>
                    <li><a class="nav-link" href="#Dose_and_method_of_administration">4.2 Dose and method of administration</a> </li>
                    <li><a class="nav-link" href="#Contraindications">4.3 Contraindications</a> </li>
                    <li><a class="nav-link" href="#Special_warnings_and_precautions_for_use">4.4 Special warnings and precautions for use</a> </li>
                    <li><a class="nav-link" href="#Interactions_with_other_medicines_and_other_forms_of_interactions">4.5 Interactions with other medicines and other forms of interactions</a> </li>
                    <li><a class="nav-link" href="#Fertility_pregnancy_and_lactation">4.6 Fertility, pregnancy and lactation</a> </li>
                    <li><a class="nav-link" href="#Effects_on_ability_to_drive_and_use_machines">4.7 Effects on ability to drive and use machines</a> </li>
                    <li><a class="nav-link" href="#Adverse_effects_Undesirable_effects">4.8 Adverse effects (Undesirable effects)</a> </li>
                    <li><a class="nav-link" href="#Overdose">4.9 Overdose</a> </li>



                </ul>

            </li>




            <li><a class="nav-link" href="#PHARMACOLOGICAL_PROPERTIES">PHARMACOLOGICAL PROPERTIES</a>
                <ul id="navbar-ul">
                    <li><a class="nav-link" href="#Pharmacodynamic_properties">5.1 Pharmacodynamic properties</a> </li>
                    <li><a class="nav-link" href="#Pharmacokinetic_properties">5.2 Pharmacokinetic properties</a> </li>
                    <li><a class="nav-link" href="#Preclinical_safety_data">5.3 Preclinical safety data</a> </li>
                    <li><a class="nav-link" href="#Preclinical_safety_data">5.4 Preclinical safety data</a> </li>
                </ul>

            </li>




            <li>
                <a class="nav-link" href="#PHARMACEUTICAL_PARTICULARS">PHARMACEUTICAL PARTICULARS</a>

                <ul id="navbar-ul">
                    <li><a class="nav-link" href="#List_of_excipients">6.1 List of excipients</a> </li>
                    <li><a class="nav-link" href="#Incompatibilities">6.2 Incompatibilities</a> </li>
                    <li><a class="nav-link" href="#Shelf_life">6.3 Shelf life</a> </li>
                    <li><a class="nav-link" href="#Special_precautions_for_storage">6.4 Special precautions for storage</a> </li>
                    <li><a class="nav-link" href="#Nature_and_contents_of_container ">6.5 Nature and contents of container </a> </li>
                    <li><a class="nav-link" href="#Special_precautions_for_disposal ">6.6 Special precautions for disposal</a> </li>
                    <li><a class="nav-link" href="#Physicochemical_properties ">6.7 Physicochemical properties</a> </li>
                </ul>
            </li>






            <li><a class="nav-link" href="#MEDICINE_SCHEDULE_POISONS_STANDARD">MEDICINE SCHEDULE (POISONS STANDARD)</a></li>


            <li><a class="nav-link" href="#SPONSOR">SPONSOR</a></li>

            <li><a class="nav-link" href="#DATE_OF_FIRST_APPROVAL">DATE OF FIRST APPROVAL</a></li>


            <li><a class="nav-link" href="#DATE_OF_REVISION">DATE OF REVISION</a></li>
        </ol>



    </nav>



    <main id="main-doc">
        <h4>This medicinal product is subject to additional monitoring in Australia. This will allow quick
            identification of new safety information. Healthcare professionals are asked to report any
            suspected adverse events at <a href="https://www.tga.gov.au/reporting-problems">www.tga.gov.au/reporting-problems.</a></h4>
        <hr>
        <header id="header">TALTZ (IXEKIZUMAB (RCH) </header>
        <header id="header">SOLUTION FOR INJECTION</header>

        <hr>
        <section class="main-section" id="NAME_OF_THE_MEDICINE">
            <header id="header">1. NAME OF THE MEDICINE</header>
            <article>
                <p>
                    Ixekizumab (rch)
                </p>
            </article>
        </section>
        <hr>

        <section class="main-section" id="QUALITATIVE_AND_QUANTITATIVE_COMPOSITION">
            <header id="header">2. QUALITATIVE AND QUANTITATIVE COMPOSITION</header>
            <article>
                <p>Each prefilled pen (autoinjector) or prefilled syringe contains ixekizumab 80 mg/mL</p>
                <p>TALTZ (ixekizumab (rch)) is a humanised immunoglobulin G subclass 4 (IgG4) monoclonal
                    antibody (mAb) with neutralising activity against interleukin-17A (IL-17A). TALTZ is
                    produced by recombinant DNA technology in a recombinant mammalian cell line and
                    purified using standard technology for bioprocessing. Ixekizumab is comprised of two
                    identical light chain polypeptides of 219 amino acids each and two identical heavy chain
                    polypeptides of 445 amino acids each.</p>
                <p>For the full list of excipients, see <b>6.1 List of excipients</b></p>

            </article>
        </section>
        <hr>



        <section class="main-section" id="PHARMACEUTICAL_FORM">
            <header id="header">3. PHARMACEUTICAL FORM</header>
            <article>

                <p>TALTZ is supplied as a solution for injection
                </p>

                <p>The TALTZ solution is sterile, preservative free, clear and colourless to slightly yellow. The
TALTZ solution has a pH of 5.3 to 6.1. TALTZ is administered as a subcutaneous (SC)
injection. TALTZ is for single use, therefore contains no antimicrobial preservative.
                </p>
                <p>TALTZ is available as a 1 mL single-dose prefilled pen (autoinjector) or a 1 mL single dose
prefilled syringe. Each autoinjector or prefilled syringe is composed of ixekizumab (80
mg/mL).</p>
                <p>The autoinjector and prefilled syringe each contain a 1 mL glass syringe with a fixed needle.
The TALTZ autoinjector and prefilled syringe are manufactured to deliver 80 mg of
ixekizumab. TALTZ is latex-free.</p>

            </article>
        </section>
        <hr>



        <section class="main-section" id="CLINICAL_PARTICULARS">
            <header id="header">4. CLINICAL PARTICULARS</header>
            <article>
                <h4 id="Therapeutic_indications">4.1 Therapeutic indications </h4>
                <p><b>Plaque psoriasis</b></p>
                <p>TALTZ is indicated for the treatment of adult patients with moderate-to-severe plaque
psoriasis who are candidates for systemic therapy or phototherapy</p>
                <p><b>Psoriatic arthritis</b></p>
                <p>TALTZ is indicated for the treatment of active psoriatic arthritis in adult patients who have
responded inadequately, or who are intolerant, to previous DMARD therapy.</p>
                <p>TALTZ may be used as monotherapy or in combination with a conventional DMARD (e.g.
methotrexate).</p>

                <h4 id="Dose_and_method_of_administration">4.2 Dose and method of administration </h4>

                <p><b>Dosage</b></p>
                <p><b>Plaque psoriasis</b></p>
                <p>The recommended dose is 160 mg by SC injection (two 80 mg injections) at Week 0, followed
by an 80 mg injection (one injection) every 2 weeks at Weeks 2, 4, 6, 8, 10 and 12, then 80 mg
(one injection) every 4 weeks.</p>
                <p><b>Psoriatic arthritis</b></p>
                <p>The recommended dose is 160 mg by SC injection (two 80 mg injections) at Week 0, followed
by 80 mg (one injection) every 4 weeks. </p>
                <p>For psoriatic arthritis patients with coexistent moderate to severe plaque psoriasis, use the
dosing regimen for plaque psoriasis.</p>
                <p><b>Elderly patients (≥65 years)</b></p>
                <p>No dose adjustment is required for elderly patients.</p>
                <p><b>Renal impairment or hepatic impairment</b></p>
                <p>TALTZ has not been studied in these patient populations. No dosage recommendations can
be made.</p>
                <p><b>Method of administration</b></p>
                <p>TALTZ is for SC injection. After training in SC injection technique, a patient may self-inject
with ixekizumab.</p>
                <p>If possible, areas of the skin that show psoriasis should be avoided as injection sites.</p>
                <p>TALTZ is for single-use in one patient only. Discard any residue product.</p>
                <p><b>Special precautions for handling</b></p>
                <p>The Instructions for Use included as a pack insert must be followed carefully.</p>
                <p>Do not use TALTZ if it has been frozen.</p>
                
                
                <h4 id="Contraindications">4.3 Contraindications </h4>
                <p>TALTZ is contraindicated in patients with known serious hypersensitivity to ixekizumab or
any of the excipients.</p>

                <h4 id="Special_warnings_and_precautions_for_use">4.4 Special warnings and precautions for use </h4>
                <p><b>Infections</b></p>
                <p>TALTZ may increase the risk of infections. In clinical trials, a higher rate of infection such as
upper respiratory tract infection, oral candidiasis, conjunctivitis and tinea infections were
observed in TALTZ treated patients compared to placebo <b>(see 4.8 Adverse effects
(Undesirable Effects)).</b></p>
                <p>TALTZ should be used with caution in patients with clinically important chronic or active
infection. Instruct patients to seek medical advice if signs or symptoms suggestive of an
infection occur. If a patient develops a serious infection or is not responding to standard
therapy the patient should be closely monitored. TALTZ should be discontinued until the
infection resolves.</p>
                
                <p>Evaluate patients for tuberculosis (TB) infection prior to initiating treatment with TALTZ. Do
not administer TALTZ to patients with active TB infection. Initiate treatment of latent TB
prior to administering TALTZ. Consider anti-TB therapy prior to initiation of TALTZ in
patients with a past history of latent or active TB in whom an adequate course of treatment
cannot be confirmed. Patients receiving TALTZ should be monitored closely for signs and
symptoms of active TB during and after treatment.
                </p>

                <p><b>Hypersensitivity</b></p>
                <p>Serious hypersensitivity reactions, including some cases of anaphylaxis, angioedema and
urticaria, have been reported. If a serious hypersensitivity reaction occurs, administration of
TALTZ should be discontinued immediately and appropriate therapy initiated.</p>
                <p><b> Inflammatory bowel disease</b></p>
                <p>Crohn’s disease and ulcerative colitis, including exacerbations, occurred at a greater
frequency in the TALTZ group (Crohn’s disease 0.1%, ulcerative colitis 0.2%) than the
placebo group (0%) during the 12-week, placebo-controlled period of the psoriasis clinical
trials.</p>
                <p>Exercise caution when prescribing TALTZ to patients with inflammatory bowel disease,
including Crohn’s disease and ulcerative colitis, as new cases or exacerbations have been
reported. Patients treated with TALTZ and have inflammatory bowel disease should be
monitored closely.</p>
                <p><b>Immunisations</b></p>
                <p>TALTZ should not be used with live vaccines. No data are available on the response to live
vaccines.</p>
                <p>In a study in healthy subjects, no safety concerns were identified following administration of
inactivated vaccines (tetanus and pneumococcal) after two doses of ixekizumab (160 mg
followed by a second dose of 80 mg two weeks later). However, there is insufficient data on
whether the immune response to these vaccines is adequate following administration of
TALTZ.</p>
                
                <p><b>Use in the elderly </b></p>
                <p>Of the 4204 psoriasis patients exposed to TALTZ in clinical trials, a total of 265 patients were
aged ≥65 years and 34 patients were aged ≥75 years. Of the 1118 PsA patients exposed to
TALTZ in clinical trials, a total of 122 patients were aged ≥65 years and 6 patients were aged
≥75 years. Although no differences in safety or efficacy were observed between older and
younger patients, the number of patients aged ≥65 years is not sufficient to determine
whether they respond differently from younger patients. <b>(See 5.2 Pharmacokinetic
properties, Special Populations, Elderly Patients (≥65 years)).</b></p>
                <p><b>Paediatric use</b></p>
                <p>Safety and effectiveness of TALTZ in paediatric patients (Less than 18 years of age) have not been
evaluated.</p>
                <p><b>Effects on laboratory tests</b></p>
                <p>No information on the effect of ixekizumab on laboratory tests is available.</p>


                <h4 id="Interactions_with_other_medicines_and_other_forms_of_interactions">4.5 Interactions with other medicines and other forms of interactions</h4>
                <p></p>


                <h4 id="Fertility_pregnancy_and_lactation">4.6 Fertility, pregnancy and lactation</h4>
                <p><u>Effects on fertility </u></p>
                <p> </p>

                <h4><u>Use in pregnancy (Pregnancy Category B1)</u></h4>
                <p></p>
                <p></p>
                <p>SKYRIZI should be used in pregnancy only if the benefits outweigh the potential risks.</p>

                <p><u>Use in lactation </u></p>
                <p></p>

                <h4 id="Effects_on_ability_to_drive_and_use_machines">4.7 Effects on ability to drive and use machines </h4>
                <p></p>

                <h4 id="Adverse_effects_Undesirable_effects">4.8 Adverse effects (Undesirable effects)</h4>
                <p></p>
                <p></p>
                <p></p>


                <img class="table" src="" alt="Table 1">⁨
                <img class="table" src="" alt="Table 2">⁨


                <h4><u>Less Common Clinical Trial Adverse Drug Reactions (less than 1%)</u></h4>
                <p></p>

                <h4><u>Specific Adverse Reactions</u></h4>
                <h4><u>Infections</u></h4>
                <p></p>
                <p></p>
                <h4><u>Long-Term Safety</u></h4>
                <p></p>
                <h4><u>Immunogenicity</u></h4>
                <p></p>
                <p></p>
                <p></p>

                <h4><u>Reporting suspected adverse effects</u></h4>
                <p>
                    <a target="_blank" "https://www.tga.gov.au/reporting-problems">www.tga.gov.au/reporting-problems.</a> In New Zealand, healthcare professionals are asked to
                    report any suspected adverse reactions at <a target="_blank" "https://nzphvc.otago.ac.nz/reporting/">https://nzphvc.otago.ac.nz/reporting/</a></p>


                <h4 id="Overdose">4.9 Overdose</h4>
                <p></p>
                <p></p>
                <p></p>

                <hr>

                <section class="main-section" id="PHARMACOLOGICAL_PROPERTIES">
                    <header id="header">5. PHARMACOLOGICAL PROPERTIES</header>
                    <article>
                        <h4 id="Pharmacodynamic_properties">5.1 Pharmacodynamic properties</h4>
                        <p></p>
                        <h4><u>Mechanism of action</u></h4>
                        <p></p>

                        <h4><u>Clinical trials</u></h4>
                        <p></p>
                        <p>O</p>
                        <p></p>

                        <h4><u>ULTIMMA-1 and ULTIMMA-2</u></h4>
                        <p></p>

                        <img class="image" src="" alt="Table-2">⁨

                        <img class="image" src="" alt="ULTIMA_pvalue">⁨

                        <img class="image" src="" alt="figure1">

                        <p></p>
                        <p></p>
                        ⁨
                        <h4><u>IMMHANCE</u></h4>

                        <p>IMMHANCE </p>
                        <p></p>
                        <p></p>
                        <h4><u>IMMVENT</u></h4>
                        <p></p>

                        <ul>
                            <li> </li>
                            <li>P</li>
                            <li></li>
                        </ul>
                        <p>S</p>

                        <img class="image" src="" alt="table3">

                        <p></p>

                        <img class="image" src="" alt="figure2">

                        <p></p>

                        <h4><u>Maintenance and Durability of Response</u></h4>
                        <p></p>
                        <h4><u>Quality of Life/Patient-Reported Outcomes</u></h4>
                        <p></p>

                        <img class="image" src="TDPimg/Table4.png" alt="table4">
                        <p></p>

                        <p></p>

                        <p></p>

                        <h4 id="Pharmacokinetic_properties">5.2 Pharmacokinetic properties</h4>
                        <h4><u>Absorption</u></h4>
                        <p></p>
                        <p></p>

                        <h4><u>Distribution</u></h4>
                        <p></p>

                        <h4><u>Metabolism</u></h4>
                        <p></p>

                        <h4><u>Excretion</u></h4>
                        <p></p>
                        <p></p>


                        <h4><u>Drug Interactions</u></h4>
                        <p></p>

                        <p></p>

                        <h4><u>Paediatrics</u></h4>
                        <p></p>

                        <h4><u>Use in the elderly</u></h4>
                        <p></b>.</p>


                        <h4><u>Renal or hepatic impairment</u></h4>
                        <p></p>
                        <p></b></p>

                        <h4><u>Body weight</u></h4>
                        <p></p>

                        <h4><u>Gender or race</u></h4>
                        <p></p>

                        <h4 id="Preclinical_safety_data">5.3 Preclinical_safety_data</h4>

                        <p></p>

                        <h4><u>Genotoxicity</u></h4>
                        <p></p>

                        <h4><u>Carcinogenicity</u></h4>
                        <p></p>

                    </article>
                </section>
                <hr>
                <section class="main-section" id="PHARMACEUTICAL_PARTICULARS">
                    <header id="header">6. PHARMACEUTICAL_PARTICULARS</header>
                    <article>
                        <h4 id="List_of_excipients">6.1 List of excipients </h4>
                        <p></p>

                        <h4 id="Incompatibilities">6.2 Incompatibilities </h4>
                        <p></p>

                        <h4 id="Shelf_life">6.3 Shelf life </h4>
                        <p></p>

                        <h4 id="Special_precautions_for_storage">6.4 Special precautions for storage</h4>
                        <p></p>

                        <h4 id="Nature_and_contents_of_container">6.5 Nature and contents of container </h4>
                        <p></p>
                        <ul>
                            <li></li>
                        </ul>


                        <h4 id="Special_precautions_for_disposal">6.6 Special precautions for disposal </h4>
                        <p></p>

                        <h4 id="Physicochemical_properties">6.7 Physicochemical properties</h4>
                        <h4><u>CAS number</u></h4>
                        <p></p>

                    </article>
                </section>

                <hr>
                <section>
                    <h4 id="MEDICINE_SCHEDULE_POISONS_STANDARD">7 MEDICINE SCHEDULE (POISONS STANDARD)</h4>
                    <p></p>
                    <hr>
                    <h4 id="SPONSOR">8 SPONSOR </h4>
                    <p></p>
                    <p></p>
                    <p></p>
                    <p></p>
                    <p></p>
                    <a href="">www.abbvie.com.au</a>
                    <p></p>
                    <p></p>
                    <p></p>
                    <p></p>
                    <p></p>
                    <a href="">www.abbvie.co.nz</a>
                    <hr>
                    <h4 id="DATE_OF_FIRST_APPROVAL">9 DATE OF FIRST APPROVAL </h4>
                    <p></p>
                    <hr>
                    <h4 id="DATE_OF_REVISION">10 DATE OF REVISION</h4>
                    <p></p>

                    <img class="image" src="" alt="Summary table of changes">

                </section>

            </article>
        </section>

        <footer>
            <img class="image" src="" alt="footer">

        </footer>
    </main>

</body>
